- Email: [email protected]
Subject Index Volume 168
Journal of Controlled Release 168 (2013) e8–e9
Contents lists available at SciVerse ScienceDirect
Journal of Controlled Release j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / j c o n r e l
Subject Index Volume 168 (2013) Active targeting, (168) 179 Administration routes, (168) 10 Adjuvants, (168) 179 Aminooxy, (168) 334 Antibody response, (168) 10 Antibody production, (168) 271 Antigen presentation, (168) 271 Alpha-fetoprotein, (168) 135 Asialoglycoprotein receptor, (168) 135 Bioavailability, (168) 50 Biocompatibility, (168) 70, (168) 209 Bioreducible nanogel, (168) 271 Bovine serum albumin, (168) 1 Cancer, (168) 88 Cancer stem cells, (168) 317 Cancer vaccines, (168) 179 CD133, (168) 317 Cell and tissue viability, (168) 209 Celecoxib, (168) 239 Colorectal cancer, (168) 317 Computational fluid dynamics, (168) 115 Conjugation, (168) 334 Controlled release, (168) 70, (168) 289, (168) 327 Cyclodextrin, (168) 28 Cytotoxic T-lymphocyte response, (168) 271 Deoxycholic acid, (168) 125 Dendritic cells, (168) 28 Dendrimer, (168) 135 Doxorubicin, (168) 105, (168) 142 Doxorubicin hydrochloride (PubChem CID: 443939), (168) 61 Drug delivery, (168) 1, (168) 18, (168) 88, (168) 262, (268) 298 Drug delivery system, (168) 298 Drug delivery systems (DDS), (168) 327 Drug eluting stents, (168) 70 Drug-eluting stents, (168) 115 Drug targeting, (168) 251 Ductal carcinoma in situ, (168) 298 Endocytosis, (168) 135 Extravasation, (168) 262 Evans blue, (168) 262 Flavonoid, (168) 50 Flash nanoprecipitation, (168) 41 Focused ultrasound, (168) 262 FoxP3+CD4+ T-cells, (168) 28
doi:10.1016/S0168-3659(13)00265-4
Functionalized implants, (168) 289 Fusion protein, (168) 307 Gastric emptying time, (168) 151 Gastric residence time, (168) 151 Gastroretentive form, (168) 151 Gene delivery, (168) 209 GDNF, (168) 307 Graft polymer, (168) 334 Gramicidin, (168) 251 Hepatocellular carcinoma, (168) 251 Herbosome, (168) 50 High-intensity focused ultrasound (HIFU), (168) 327 Hyaluronan, (168) 334 Hyaluronic acid, (168) 105 Hydrogel, (168) 166 Hyperthermia, (168) 142 Immunotherapy, (168) 179 Immunotoxin, (168) 317 Interferon, (168) 200 Interleukin-10 cytokine, (168) 209 Iontophoresis, (168) 298 Inflammatory bowel disease, (168) 28 Insulin-like growth factor-1, (168) 166 Intrarectal administration, (168) 28, (168) 228 Intravital microscopy, (168) 142 In vivo, (168) 10 Liver cancer, (168) 1 Low molecular weight PEI, (168) 125 Lung cancer, (168) 239 Lymphatic, (168) 200 Macrophage, (168) 41 Mannose receptor, (168) 41 Magneto-thermo-chemotherapy, (168) 280 Malaria DNA vaccine, (168) 10 Metastasis, (168) 200 Mesenchymal stem cells (MSC), (168) 225 Microbubbles, (168) 262 Milk duct, (168) 298 Microparticle, (168) 307 Microparticles, (168) 18 Migrating myoelectric cycle, (168) 151 Mineralization, (168) 105 Miproxifen, (168) 298 Molecular therapy, (168) 298
Subject Index Volume 167 (2013) e8–e9
MR imaging, (168) 280 Murine model of acute-colitis, (168) 28 Multidrug resistance, (168) 135 Myocardial apoptosis, (168) 125 Myocardial ischemia–reperfusion injury, (168) 125 Nanomedicine, (168) 88 Nanosuspensions, (168) 77 Nanoparticle, (168) 41 Nanoparticles, (168) 1, (168) 105, (168) 179, (168) 251, (168) 327 Nanoparticles (NPs), (168) 225 Nanotherapeutics, (168) 289 Nerve regeneration, (168) 289 Neuronal differentiation, (168) 307 Neuropathic pain, (168) 209 Novel drug carrier, (168) 50 Non-viral vector, (168) 209 Osteochondral defect, (168) 166 Osteogenesis, (168) 18 Osmotic pumps, (168) 77 Osteosarcoma (OS), (168) 225 Organ distribution, (168) 77 Oxime, (168) 334 Pharmacokinetics, (168) 115, (168) 200 PDLLGA, (168) 18 PEGylation, (168) 200 Phosphatidylcholine, (168) 50 Photochemical internalization, (168) 317 Photodynamic therapy, (168) 88, (168) 102, (168) 317 Photodynamic therapy (PDT), (168) 225 Porphyrins (TPPS), (168) 225 PLGA, (168) 307 PLGA and TMC-TPP nanoparticles, (168) 35 Polyelectrolyte multilayers, (168) 289 Polymersomes, (168) 280 Primary breast cancer, (168) 298
Pulmonary delivery, (168) 239 Porous microparticles, (168) 239 Phytophospholipid complex, (168) 50 Pulsatile blood flow, (168) 115 Radioimaging, (168) 77 Raft forming system, (168) 151 Rapamycin, (168) 70 Release regulation, (168) 307 Retinoic acid (RA), (168) 35 Retinaldehyde dehydrogenase enzyme (RALDH), (168) 35 SHP-1 siRNA, (168) 125 siRNA nanoplexes, (168) 289 Stability, (168) 105 SPECT, (168) 262 Stem cells, (168) 18 Simvastatin, (168) 18 siRNA delivery, (168) 28 Stimuli-triggered drug release, (168) 280 Subcutaneous, (168) 77 Superparamagnetic iron oxide nanoparticles, (168) 280 Supercritical fluid, (168) 239 SPIONs, (168) 10 Targeting, (168) 1 Targeted delivery, (168) 135 Targeted drug delivery, (168) 41 Targeted nanoparticles, (168) 88 Thermosensitive liposomes, (168) 142, (168) 327 Transforming growth factor-β3, (168) 166 Triggered drug release, (168) 142 Triggered release, (168) 327 Tumor-targeting, (168) 280 Tumor growth control, (168) 142 TNF-α, (168) 28 Vaccine adjuvant, (168) 271
e9
Contents lists available at SciVerse ScienceDirect
Journal of Controlled Release j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / j c o n r e l
Subject Index Volume 168 (2013) Active targeting, (168) 179 Administration routes, (168) 10 Adjuvants, (168) 179 Aminooxy, (168) 334 Antibody response, (168) 10 Antibody production, (168) 271 Antigen presentation, (168) 271 Alpha-fetoprotein, (168) 135 Asialoglycoprotein receptor, (168) 135 Bioavailability, (168) 50 Biocompatibility, (168) 70, (168) 209 Bioreducible nanogel, (168) 271 Bovine serum albumin, (168) 1 Cancer, (168) 88 Cancer stem cells, (168) 317 Cancer vaccines, (168) 179 CD133, (168) 317 Cell and tissue viability, (168) 209 Celecoxib, (168) 239 Colorectal cancer, (168) 317 Computational fluid dynamics, (168) 115 Conjugation, (168) 334 Controlled release, (168) 70, (168) 289, (168) 327 Cyclodextrin, (168) 28 Cytotoxic T-lymphocyte response, (168) 271 Deoxycholic acid, (168) 125 Dendritic cells, (168) 28 Dendrimer, (168) 135 Doxorubicin, (168) 105, (168) 142 Doxorubicin hydrochloride (PubChem CID: 443939), (168) 61 Drug delivery, (168) 1, (168) 18, (168) 88, (168) 262, (268) 298 Drug delivery system, (168) 298 Drug delivery systems (DDS), (168) 327 Drug eluting stents, (168) 70 Drug-eluting stents, (168) 115 Drug targeting, (168) 251 Ductal carcinoma in situ, (168) 298 Endocytosis, (168) 135 Extravasation, (168) 262 Evans blue, (168) 262 Flavonoid, (168) 50 Flash nanoprecipitation, (168) 41 Focused ultrasound, (168) 262 FoxP3+CD4+ T-cells, (168) 28
doi:10.1016/S0168-3659(13)00265-4
Functionalized implants, (168) 289 Fusion protein, (168) 307 Gastric emptying time, (168) 151 Gastric residence time, (168) 151 Gastroretentive form, (168) 151 Gene delivery, (168) 209 GDNF, (168) 307 Graft polymer, (168) 334 Gramicidin, (168) 251 Hepatocellular carcinoma, (168) 251 Herbosome, (168) 50 High-intensity focused ultrasound (HIFU), (168) 327 Hyaluronan, (168) 334 Hyaluronic acid, (168) 105 Hydrogel, (168) 166 Hyperthermia, (168) 142 Immunotherapy, (168) 179 Immunotoxin, (168) 317 Interferon, (168) 200 Interleukin-10 cytokine, (168) 209 Iontophoresis, (168) 298 Inflammatory bowel disease, (168) 28 Insulin-like growth factor-1, (168) 166 Intrarectal administration, (168) 28, (168) 228 Intravital microscopy, (168) 142 In vivo, (168) 10 Liver cancer, (168) 1 Low molecular weight PEI, (168) 125 Lung cancer, (168) 239 Lymphatic, (168) 200 Macrophage, (168) 41 Mannose receptor, (168) 41 Magneto-thermo-chemotherapy, (168) 280 Malaria DNA vaccine, (168) 10 Metastasis, (168) 200 Mesenchymal stem cells (MSC), (168) 225 Microbubbles, (168) 262 Milk duct, (168) 298 Microparticle, (168) 307 Microparticles, (168) 18 Migrating myoelectric cycle, (168) 151 Mineralization, (168) 105 Miproxifen, (168) 298 Molecular therapy, (168) 298
Subject Index Volume 167 (2013) e8–e9
MR imaging, (168) 280 Murine model of acute-colitis, (168) 28 Multidrug resistance, (168) 135 Myocardial apoptosis, (168) 125 Myocardial ischemia–reperfusion injury, (168) 125 Nanomedicine, (168) 88 Nanosuspensions, (168) 77 Nanoparticle, (168) 41 Nanoparticles, (168) 1, (168) 105, (168) 179, (168) 251, (168) 327 Nanoparticles (NPs), (168) 225 Nanotherapeutics, (168) 289 Nerve regeneration, (168) 289 Neuronal differentiation, (168) 307 Neuropathic pain, (168) 209 Novel drug carrier, (168) 50 Non-viral vector, (168) 209 Osteochondral defect, (168) 166 Osteogenesis, (168) 18 Osmotic pumps, (168) 77 Osteosarcoma (OS), (168) 225 Organ distribution, (168) 77 Oxime, (168) 334 Pharmacokinetics, (168) 115, (168) 200 PDLLGA, (168) 18 PEGylation, (168) 200 Phosphatidylcholine, (168) 50 Photochemical internalization, (168) 317 Photodynamic therapy, (168) 88, (168) 102, (168) 317 Photodynamic therapy (PDT), (168) 225 Porphyrins (TPPS), (168) 225 PLGA, (168) 307 PLGA and TMC-TPP nanoparticles, (168) 35 Polyelectrolyte multilayers, (168) 289 Polymersomes, (168) 280 Primary breast cancer, (168) 298
Pulmonary delivery, (168) 239 Porous microparticles, (168) 239 Phytophospholipid complex, (168) 50 Pulsatile blood flow, (168) 115 Radioimaging, (168) 77 Raft forming system, (168) 151 Rapamycin, (168) 70 Release regulation, (168) 307 Retinoic acid (RA), (168) 35 Retinaldehyde dehydrogenase enzyme (RALDH), (168) 35 SHP-1 siRNA, (168) 125 siRNA nanoplexes, (168) 289 Stability, (168) 105 SPECT, (168) 262 Stem cells, (168) 18 Simvastatin, (168) 18 siRNA delivery, (168) 28 Stimuli-triggered drug release, (168) 280 Subcutaneous, (168) 77 Superparamagnetic iron oxide nanoparticles, (168) 280 Supercritical fluid, (168) 239 SPIONs, (168) 10 Targeting, (168) 1 Targeted delivery, (168) 135 Targeted drug delivery, (168) 41 Targeted nanoparticles, (168) 88 Thermosensitive liposomes, (168) 142, (168) 327 Transforming growth factor-β3, (168) 166 Triggered drug release, (168) 142 Triggered release, (168) 327 Tumor-targeting, (168) 280 Tumor growth control, (168) 142 TNF-α, (168) 28 Vaccine adjuvant, (168) 271
e9